Viz.ai Wins 2025 Edison Award™ for Machine Learning Innovation for Third Year
Viz.ai, a leader in artificial intelligence (AI)-powered disease detection and intelligent care coordination, has announced its recognition as an Award Winner in the 2025 Edison Awards, marking the third consecutive year the company has been honored. Viz.ai’s AI-powered software solution, Viz HCM, was awarded in the Health Medical & Biotech category under the Cardiovascular Health Diagnostics and Monitoring subcategory. The Edison Awards, named after the iconic American inventor Thomas Alva Edison, are prestigious honors that celebrate excellence in product and service innovation, marketing, design, and overall business success. They are widely recognized as one of the most significant accolades for innovation across industries.
Dr. Chris Mansi, CEO and co-founder of Viz.ai, expressed immense pride in the achievement. “We are thrilled to receive our third Edison Award, which reaffirms our commitment to transforming healthcare through AI-driven technology,” Dr. Mansi stated. “Hypertrophic cardiomyopathy (HCM) is an underdiagnosed condition and the most commonly inherited heart disease. Unfortunately, only about 15% of these patients are properly diagnosed. The recognition of Viz HCM reinforces our efforts to help clinicians diagnose and treat this serious disease faster and more effectively, improving outcomes for patients.”
Viz HCM is an AI-powered software solution designed to detect signs of hypertrophic cardiomyopathy (HCM), a heart condition that often goes undiagnosed. HCM can lead to severe health complications, including heart failure or sudden cardiac arrest. The software analyzes 12-lead electrocardiograms (ECGs) across a health system, identifying suspected cases of HCM, notifying cardiology care teams, and ultimately increasing the likelihood that patients will receive timely follow-up and accurate diagnoses. This early detection allows healthcare providers to intervene sooner, ensuring better care and preventing complications associated with undiagnosed HCM.
Viz HCM is the result of a multi-year partnership between Viz.ai and Bristol Myers Squibb (NYSE: BMY). The software was granted De Novo approval by the U.S. Food and Drug Administration (FDA) in August 2023, a landmark achievement that created a new regulatory category for cardiovascular machine learning-based notification software. This approval underscores Viz HCM’s potential to revolutionize the detection and diagnosis of cardiovascular diseases using cutting-edge AI technology.
Recent data presented at the American College of Cardiology meeting highlighted the effectiveness of Viz HCM in a real-world clinical setting. In a nine-month period at the Cleveland Clinic, one of the leading academic hospitals, Viz HCM successfully identified 574 patients with HCM, demonstrating its ability to enhance disease detection and improve diagnostic accuracy. This data adds to the growing body of evidence supporting the efficacy of AI-powered tools in the healthcare industry.
The Edison Awards have a rigorous judging process, with nominations reviewed by a diverse panel of over 2,000 senior business executives and academic professionals. This panel includes experts from various fields, including product development, engineering, marketing, design, and science, along with past Edison Award winners. The panel’s extensive expertise ensures that only the most innovative and impactful products and services are recognized.
The winners of the 2025 Edison Awards were announced at a prestigious Gala held on April 3, 2025, in Fort Myers, Florida. This year’s event brought together industry leaders, innovators, and experts to celebrate the groundbreaking achievements in technology, business, and product development across various sectors.
The Role of Viz.ai in Healthcare Innovation
Viz.ai is a trailblazer in the use of artificial intelligence (AI) algorithms and machine learning to accelerate the speed of diagnosis and improve care coordination across healthcare systems. The company’s AI-powered platform, Viz.ai One®, is used in over 1,700 hospitals and healthcare systems across the U.S. and Europe. The platform identifies patients with suspected conditions, informs critical clinical decisions, and optimizes care pathways to improve patient outcomes.
Viz.ai One® also enables real-time collaboration among care teams, helping to streamline workflows and improve operational efficiency. By providing accurate, data-driven insights, the platform assists healthcare providers in making faster, more informed decisions at the point of care, ultimately leading to better patient outcomes. This integrated care coordination solution is backed by real-world clinical evidence, ensuring its reliability and effectiveness in enhancing healthcare delivery.
As the healthcare industry increasingly turns to AI to improve diagnosis, treatment, and patient care, Viz.ai remains at the forefront of this transformation. The company’s AI-driven solutions are not only enhancing disease detection but are also helping to bridge the gap between patients and providers, reducing delays in care and improving the overall patient experience.
